910 abstracts found.



Results filter

Cardiovascular toxicity in paediatric cancer treatment

Year:

Session type: ,

Steven Lipshultz1,2

1Children’s Hospital of Michigan, Detroit, Michigan, USA,2Wayne State University, Detroit, Michigan, USA


Using the Patient care Outcome Scale (POS) in palliative care and oncology: international experiences from research, clinical practice and education

Year:

Session type: ,

Irene Higginson1

1King’s College London, London, UK


“Intravital imaging reveals how stroma dictates heterogeneous responses to targeted therapy”

Year:

Session type: ,

Erik Sahai1

1The Francis Crick Institute, London, UK


Molecular Risk Stratification for Aspirin Chemoprevention

Year:

Session type: ,

Andrew Chan1

1Massachusetts General Hospital, Boston, MA, USA


Changing the paradigm for therapeutic progress for rare tumors: SPECTArare “Optimizing molecular profiling technologies through partnerships”

Year:

Session type: ,

Denis Lacombe1

1EORTC, Brussels, Belgium


Identification and triage of patient and carer needs: a clinician-rated tool for the clinic or surgery

Year:

Session type: ,

Miriam Johnson1

1University of Hull, Hull, UK


Novel intrapatient dose escalation phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 in BRCA1/2 and non-BRCA1/2 mutation patients with advanced cancers

Year:

Session type: ,

Timothy Yap1,2

1The Institute of Cancer Research, London, UK,2Royal Marsden Hospital, London, UK


Operationalising needs-based assessment

Year:

Session type: ,

David Currow1

1Flinders University, Adelaide, Australia


Benefits and Harms of Preventive Therapy for Cancer

Year:

Session type: ,

Jack Cuzick1

1Queen Mary University of London, London, UK


Circulating tumour cells and plasma DNA for non-invasive monitoring of cancers during their treatment

Year:

Session type: ,

Michael Speicher1

1Medical University of Graz, Graz, Austria


The future role of primary care in cancer control – survivorship care

Year:

Session type: ,

Annette Berendsen1

1University of Groningen, Groningen, The Netherlands


microRNA mechanism and its involvement in DNA damage response pathway

Year:

Session type: ,

Martin Bushell1

1MRC Toxicology Unit, Leicester, UK


Trends in electronic cigarette use in England

Year:

Session type: ,

Robert West1

1UCL, London, UK


DEBIOC: A Combinations Alliance Study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma

Year:

Session type: ,

Anne Thomas1

1University of Leicester, Leicester, UK


What can observational studies tell us about early diagnosis of symptomatic cancer?

Year:

Session type: ,

Willie Hamilton1

1University of Exeter, Exeter, UK


Can we do RCTs of interventions to expedite the diagnosis of symptomatic cancer? And should we?

Year:

Session type: ,

Richard Neal1

1Bangor University, Bangor, UK


It takes a team: the importance of integration between primary care and cancer specialist care.

Year:

Session type: ,

Eva Grunfeld1

1Ontario Institute for Cancer Research, Toronto, Canada,2University of Toronto, Toronto, Canada


How do health economists value personalised medicine in oncology?

Year:

Session type: ,

Maarten IJzerman1

1University of Twente, Enschede, The Netherlands


Key role of AGO2 and the 8q24 amplicon in regulation of microRNA biogenesis in cancer

Year:

Session type: , ,

Theme:

Laura Winchester1,Simon Wigfield1,Syed Haider1,Alan McIntyre1,Adrian Harris1,Francesca Buffa1

1University of Oxford, Oxford, UK


Mutations in the transcriptional repressor REST predispose to Wilms tumour

Year:

Session type: , ,

Theme:

Shazia Mahamdallie1,Sandra Hanks1,Kristen Karlin2,3,Anna Zachariou1,Elizabeth Perdeaux1,Elise Ruark1,Chad Shaw3,Alexander Renwick3,Emma Ramsay1,Shawn Yost1,Anna Elliot1,The Wilms Tumor Susceptibility Collaboration (WTSC)1,Michael Capra4,Thomas McLean5,Anthony Renwick1,Sheila Seal1,Charles Stiller6,Neil Sebire7,Thomas Westbrook2,3,Nazneen Rahman1,8

1Division of Genetics & Epidemiology, Institute of Cancer Research, London, UK,2Verna & Marrs McLean Dept. of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA,3Dept of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA,4Our Lady’s Children’s Hospital, Dublin, UK,5Wake Forest University School of Medicine, Winston-Salem, USA,6Public Health England, Oxford, UK,7Dept of Histopathology and Paediatric Laboratory Medicine, Great Ormond Street Hospital, London, UK,8Cancer Genetics Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK


A randomised trial of interventions to increase uptake of cervical screening among 25 year old non-attenders; final results of the STRATEGIC Trial.

Year:

Session type: , ,

Theme:

Henry Kitchener1,Matthew Gittins2,Carly Moseley1,Margaret Cruickshank3,Samantha Fletcher1,Jamie Oughton1,Rebecca Albrow1,Emma Crosbie1,Chris Roberts2

1Institute of Cancer Sciences, University of Manchester, Manchester, UK,2Institute of Population Health, University of Mancchester, Manchester, UK,3Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen, UK


Can WBRT be omitted in NSCLC patients with brain metastases not suitable for stereotactic radiosurgery or surgical resection? Results from the UK Medical Research Council QUARTZ randomised clinical trial.

Year:

Session type: , ,

Theme:

Paula Mulvenna1,Matthew Nankivell2,Rachael Barton3,Corinne Faivre-Finn4,Paula Wilson5,Barbara Moore6,Elaine McColl7,Iona Brisbane8,Dave Ardron2,Benjamin Sydes2,Cheryl Pugh2,Tanya Holt9,Neil Bayman4,Sally Morgan10,Caroline Lee11,Kathryn Waite12,Richard Stephens2,Max Parmar2,Ruth Langley2

1Northern Centre for Cancer Care, Newcastle upon Tyne, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Castle Hill Hospital, East Yorkshire, UK,4The Christie, Manchester, UK,5Bristol Haematology & Oncology Centre, Bristol, UK,6University Hospital Llandough, South Glamorgan, UK,7Royal Victoria Infirmary, Newcastle upon Tyne, UK,8Beatson West of Scotland Cancer Centre, Glasgow, UK,9Mater Hospital, Brisbane, Queensland, Australia,10Nottingham University Hospitals, Nottingham, UK,11Weston Park Hospital, Sheffield, UK,12Queen Elizabeth Hospital, King’s Lynn, UK


5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer [CRUK/06/016]: report from the CHHiP Trial Management Group

Year:

Session type: , ,

Theme:

Emma Hall1,Isabel Syndikus2,Helen Mossop1,John Staffurth3,Christopher Scrase4,Miguel Panades5,Julian Money-Kyrle6,John Logue7,Vincent Khoo8,John Graham9,David Bloomfield10,Alison Birtle11,Jean Tremlett10,Olivia Naismith8,Helen Mayles2,Shama Hassan1,Clare Cruickshank1,Clare Griffin1,David Dearnaley1,8

1The Institute of Cancer Research, London, UK,2Clatterbridge Cancer Centre, Wirral, UK,3Velindre Cancer Centre, Cardiff, UK,4Ipswich Hospital, Ipswich, UK,5Lincoln County Hospital, Lincoln, UK,6Royal Surrey County Hospital, Guildford, UK,7Christie Hospital, Manchester, UK,8Royal Marsden NHS Trust, London, UK,9Musgrove Park Hospital, Taunton, UK,10Royal Sussex County Hospital, Brighton, UK,11Royal Preston Hospital, Preston, UK


Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Year:

Session type: , ,

Theme:

Richard Hubner1,Li-Tzong Chen2,3,Daniel D. Von Hoff4,5,Chung-Pin Li6,7,Andrea Wang-Gillam8,György Bodoky9,Andrew Dean10,Yan-Shen Shan2,3,Gayle Jameson5,11,Teresa Macarulla12,13,Kyung-Hun Lee14,Jean-Frédéric Blanc15,Chang-Fang Chiu16,Gilberto Schwartsmann17,Jens T. Siveke18,Fadi S. Braiteh19,Victor M. Moyo20,Bruce Belanger20,Eliel Bayever20,David Cunningham21

1The Christie NHS Foundation Trust, Manchester, UK,2National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan,3National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan,4HonorHealth, Scottsdale, AZ, USA,5TGen, Scottsdale, AZ, USA,6Taipei Veterans General Hospital, Taipei, Taiwan,7National Yang-Ming University, Taipei, Taiwan,8Washington University in St. Louis, St. Louis, MO, USA,9St László Teaching Hospital, Budapest, Hungary,10St John of God Hospital, Subiaco, Western Australia, Australia,11Scottsdale Healthcare, Scottsdale, AZ, USA,12Vall d’Hebron University Hospital, Barcelona, Spain,13Vall d’Hebron Institute of Oncology, Barcelona, Spain,14Seoul National University Hospital, Seoul, Republic of Korea,15Hôpital Saint-André, Bordeaux, France,16China Medical University Hospital, Taichung, Taiwan,17Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil,18Klinikum rechts der Isar der TU München, Munich, Germany,19Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA


Physical activity levels and barriers to exercise referral among patients with cancer

Year:

Session type: , ,

Theme:

Dorothy Yang1,Omar Hausien1,Mohammed Aqeel1,Alexios Klonis1,Jo Foster2,Derek Renshaw3,Robert Thomas4

1University of Cambridge School of Clinical Medicine, Cambridge, UK,2Macmillan Cancer Support, London, UK,3Coventry University, Coventry, UK,4Addenbrooke’s Cambridge University Hospitals NHS Trust, Cambridge, UK,5Bedford Hospital NHS Trust, Bedford, UK


Effect of pre-diagnostic NSAID use on ovarian cancer survival

Year:

Session type: , ,

Theme:

Chris Brown1,Thomas Ian Barron2,Kathleen Bennett2,Linda Sharp1,3

1National Cancer Registry Ireland, Cork, Ireland,2Trinity College Dublin, Dublin, Ireland,3Newcastle University, Newcastle, UK


Mutations in the transcriptional repressor REST predispose to Wilms tumour

Year:

Session type:

Theme:

Shazia Mahamdallie1,Sandra Hanks1,Kristen Karlin2,3,Anna Zachariou1,Elizabeth Perdeaux1,Elise Ruark1,Chad Shaw3,Alexander Renwick3,Emma Ramsay1,Shawn Yost1,Anna Elliot1,The Wilms Tumor Susceptibility Collaboration (WTSC)1,Michael Capra4,Thomas McLean5,Anthony Renwick1,Sheila Seal1,Charles Stiller6,Neil Sebire7,Thomas Westbrook2,3,Nazneen Rahman1,8

1Division of Genetics & Epidemiology, Institute of Cancer Research, London, UK,2Verna & Marrs McLean Dept. of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA,3Dept of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA,4Our Lady’s Children’s Hospital, Dublin, UK,5Wake Forest University School of Medicine, Winston-Salem, USA,6Public Health England, Oxford, UK,7Dept of Histopathology and Paediatric Laboratory Medicine, Great Ormond Street Hospital, London, UK,8Cancer Genetics Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK


BACR Translational Award winner: Implementing personalised medicine in melanoma patients

Year:

Session type: ,


E-cadherin deficiency a novel determinant of ROS1 inhibitor sensitivity

Year:

Session type: , ,

Theme:

Ilirjana Bajrami1,Stephen Pettitt1,Rachel Brough1,Helen Pemberton1,Jessica Frankum1,James Campbell1,Alan Ashworth2,Christopher Lord1

1ICR, LONDON, UK,2UCSF, SAN FRANCISCO, USA


MAMMO-50: The results of the pre-planned internal 2 year feasibility study for Mammographic surveillance in early breast cancer patients over 50 years of age at diagnosis

Year:

Session type: , ,

Theme:

J.A. Dunn1,P.K Donnelly2,A. Marshall1,M. Wilcox3,E. Watson4,M. Ramirez1,S. Hartup5,P. Mistry1,A. J. Maxwell6,A. J Evans7

1Warwick Clinical Trials Unit, Coventry, UK,2South Devon Healthcare NHS Foundation Trust, Torquay, UK,3Independent Cancer Patient Voices, London, UK,4Department of Clinical Healthcare, Oxford Brookes University, Oxford, UK,5St James’s University Hospital, Leeds, UK,6University Hospital of South Manchester NHS Foundation Trust, Manchester, UK,7Ninewells Medical School, Dundee, UK


Gain-of-function screens as a discovery tool for regulators of response to ionising radiation and novel drug targets

Year:

Session type: ,

Theme:

Crispin Hiley1,Su Kit Chew2,Andrew Rowan1,Sheena Patel3,Charles Swanton1

1The Crick Institute, London, UK,2The UCL Cancer Institute, London, UK,3Cancer Research Technology Technology, London, UK


Exploiting synthetic lethality to kill H3K36me3-deficient cancers by WEE1 inhibition

Year:

Session type: ,

Theme:

Sophia X Pfister1,Enni Markkanen1,Yanyan Jiang1,Sovan Sarkar1,Mick Woodcock1,Chen-Chun Pai1,Lykourgos-Panagiotis Zalmas1,Giulia Orlando1,Neele Drobnitzky1,Grigory Dianov1,Songmin Ying3,Nicholas B La Thangue2,Vincenzo D’Angiolella1,Anderson Ryan1,Timothy C Humphrey1

1CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK, Oxford, UK,2Laboratory of Cancer Biology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK, Oxford, UK,33Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital, and Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China., Hangzhou, China


Targeted next-generation sequencing: cell-free DNA profiles mirror the heterogeneity of single CTCs

Year:

Session type: , ,

Theme:

David Guttery1,Karen Page1,Allison Hills2,Laura Woodley2,Genny Buson3,Raimo Tanzi3,Henrik Tommerup3,Justin Stebbing2,Charles Coombes2,Jacqueline Shaw1

1Department of Cancer Studies and Cancer Research UK Leicester Centre, Leicester, UK,2Imperial College, Department of Surgery and Cancer, Charing Cross Hospital, London, UK,3Silicon Biosystems, Bologna, Italy


The splicing inhibitor Spliceostatin A downmodulates Mcl-1 expression and induces a potent apoptotic response in Chronic Lymphocytic Leukaemia cells

Year:

Session type: , ,

Theme:

Marta Larrayoz1,Stuart J Blakemore1,Rachel Dobson1,Matthew JJ Rose-Zerilli1,Renata Walewska2,Matthew D Blunt1,Minoru Yoshida3,David Oscier2,Mark S Cragg1,Andrew J Steele1,Jonathan C Strefford1

1Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK,2Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK,3Cehmical Genomics Group, RIKEN Center for Sustainable Resource Science, Wako, Japan


CTEN (C-terminal Tensin-like) regulates head and neck cancer invasion and survival

Year:

Session type: , ,

Theme:

Jason Fleming1,Veronika Jenei1,Karwan Moutasim1,Matthew Ward1,Emma King1,4,Sassan Hafizi2,Dae Kim3,Jeremy Blaydes1,Gareth Thomas1

1University of Southampton, Southampton, UK,2University of Portsmouth, Portsmouth, UK,3St. George’s University Hospitals, London, UK,4Poole Hospital NHS Foundation Trust, Poole, UK


Trajectories of quality of life, health status and personal wellbeing in the two years following curative intent treatment for colorectal cancer: results from the UK ColoREctal Wellbeing (CREW) cohort study

Year:

Session type: ,

Theme:

Claire Foster1,3,Joanne Haviland1,3,Jane Winter2,3,Chloe Grimmett1,3,Kim Chivers Seymour3,Lynn Batehup3,Lynn Calman1,3,Jessica Corner3,Amy Din1,3,Deborah Fenlon3,Christine M May1,3,Peter W Smith4,Alison Richardson2,3

1Macmillan Survivorship Research Group, Faculty of Health Sciences, University of Southampton, Southampton, UK,2University Hospital Southampton NHS Foundation Trust, Southampton, UK,3Faculty of Health Sciences, University of Southampton, Southampton, UK,4Southampton Statistical Sciences Research Institute, University of Southampton, Southampton, UK


Symptoms and quality of life in multiple myeloma – a longitudinal study of predictive factors

Year:

Session type: ,

Theme:

Christina Ramsenthaler1,Caty Pannell1,Paramjote Kaler1,Wei Gao1,Richard Siegert2,Polly Edmonds3,Steve A. Schey4,Irene J. Higginson1

1Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, King’s College London, London, UK,2School of Public Health and Social Studies and School of Rehabilitation, University of Auckland, Auckland, New Zealand,3Department of Palliative Care, King’s College Hospital, London, UK,4Department of Haematological Medicine, King’s College Hospital, London, UK


Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role for VEGF activation through NHEJ

Year:

Session type: ,

Theme:

Natividad Gomez-Roman1,Katrina Stevenson1,Lesley Gilmour1,Anthony Chalmers1

1University of Glasgow, Glasgow, UK


Signatures of ionising radiation in second malignancies

Year:

Session type: , ,

Theme:

Sam Behjati1,Gunes Gundem1,David Wedge1,Patrick Tarpey1,Nicole Roberts1,Andrea Richardson2,Ultan McDermott1,Steven Bova3,Adrienne Flanagan4,Michael Stratton1,Peter Campbell1

1Wellcome Trust Sanger Institute, Hinxton, UK,2Harvard Medical School, Boston, UK,3University of Tampere and Fimlab Laboratories, Tampere, Finland,4University College London, London, UK


A National Platform for Molecular Diagnostics: Results from Phase I of the Cancer Research UK Stratified Medicine Programme

Year:

Session type: , ,

Theme:

Colin R Lindsay1,Emily Shaw1,James D Brenton2,Rachel Butler3,Jim Davies4,David Gonzalez de Castro5,Mike Griffiths6,Andrew Hanby7,Steve Harris4,David J Harrison8,Stephen R D Johnston9,Malcolm Mason10,Dion Morton11,Andrew G Nicholson12,Karin Oien13,Doris Rassl14,Jane Rogan15,Ian Walker1,Peter W M Johnson1

1Cancer Research UK, London, UK,2Cancer Research UK Cambridge Institute, Cambridge, UK,3Institute of Medical Genetics, Cardiff, UK,4University of Oxford, Oxford, UK,5The Centre for Molecular Pathology, Surrey, UK,6West Midlands Regional Genetics Laboratory, Birmingham, UK,7Leeds Institute of Cancer and Pathology, Leeds, UK,8University of St. Andrews, St. Andrews, UK,9The Royal Marsden NHS Foundation Trust, London, UK,10Cardiff University, Cardiff, UK,11The Queen Elizabeth Hospital, Birmingham, UK,12Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK,13NHS Greater Glasgow and Clyde, Glasgow, UK,14Papworth Hospital NHS Foundation Trust, Cambridge, UK,15Manchester Cancer Research Centre, Manchester, UK


Real-Time Diagnosis of Ovarian Cancer with the Surgical Intelligent Knife (iKnife)

Year:

Session type: , ,

Theme:

David Phelps1,Julia Balog1,2,Mona El-Bahrawy1,Abigail Speller1,Zoltan Takats1,Robert Brown1,Sadaf Ghaem-Maghami1

1Imperial College, London, UK,2Waters Corporation, Budapest, Hungary


Palliative care referrals by general practitioners in the United Kingdom: an observational study of cancer patients who died in 2000-2008

Year:

Session type: ,

Theme:

Wei Gao1,Martin Gulliford2,Irene Higginson1

1King’s College London, Cicely Saunders Institute, Department of Palliative Care, Policy and Rehabilitation, London, UK,2King’s College London,Division of Health and Social Care Research, London, UK


Public understanding of the purpose of cancer screening: a population-based survey

Year:

Session type: , ,

Theme:

Jo Waller1,Yasemin Hirst1,Jane Wardle1,Christian von Wagner1

1UCL, London, UK


PD-L1 blockade improves response of pancreatic adenocarcinoma to radiotherapy

Year:

Session type: ,

Theme:

Abul Azad1,Zenobia D’Costa1,Owen Sansom2,W.Gillies McKenna1,Ruth Muschel1,Emmanouil Fokas1

1Cancer Research UK/MRC Oxford Institute for Radiation Oncology, Oxford, UK,2Cancer Research UK Beatson Institute, Glasgow, Institute of Cancer Sciences, University of Glasgow, Glasgow, Glasgow, UK


Variations in GPs’ Decisions to Investigate Suspected Lung Cancer: A Factorial Experiment Using Multimedia Vignettes

Year:

Session type: , ,

Theme:

Jessica Sheringham1,Rachel Sequeira1,Jonathan Myles2,Willie Hamilton3,Joe McDonnell4,Judith Offman2,Stephen Duffy2,Rosalind Raine0

1UCL, London, UK,2QMUL, London, UK,3University of Exeter, Exeter, UK,4London Borough of Waltham Forest, London, UK


EURAMOS-1: an international collaboration for osteosarcoma

Year:

Session type: ,

Theme:

Jeremy S Whelan1,Matthew R Sydes10,Stefan S Bielack2,Sigbjørn Smeland4,Neyssa Marina3,Gordana Jovic10,Trude Butterfass-Bahloul5,Gabriele Calaminus6,Mikael Eriksson7,Hans Gelderblom8,Richard G Gordlick9,Pancras Hogendoorn8,Jane Hook10,Leo Kager11,Mark D Krailo12,Thomas Khüne13,R Lor Randall14,Kirsten Sundby Hall4,Lisa A Teot15,Mark Bernstein16

1University College Hospital, London, UK,2Olgahospital, Klinikum Stuttgart, Stuttgart, Germany,3Stanford University School of Medicine, Palo Alto, CA, USA,4Oslo University Hospital, The Norwegian Radium Hospital, Scandinavian Sarcoma Group, Oslo, Norway,5Center for Clinical Trials, University of Münster,, Münster, Germany,6University Hospital of Münster, Münster, Germany,7Skane University Hospital and Lund University, Lund, Sweden,8Leiden University Medical Center, Leiden, The Netherlands,9The Children’s Hospital, Bronx, NY, USA,10MRC Clinical Trials Unit at UCL, London, UK,11St Anna Children’s Hospital, Vienna, Austria,12Childrens Oncology Group, Arcadia, CA, USA,13University Children’s Hospital Basel, Basel, Switzerland,14Huntsman Cancer Inst, Salt Lake City, UT, USA,15Children’s Hospital Boston, Boston, MA, USA,16IWK Health Centre, Halifax, NS, Canada


Detection of brain tumours using translational molecularly targeted magnetic resonance imaging

Year:

Session type: ,

Theme:

Sébastien Serres1,Matthew Kirkman1,Nick de Pennington1,Claire Bristow1,Nicola R Sibson1

1Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford,, Oxford, UK


Children’s Cancer and Leukaemia Group (CCLG) McElwain Award winner – Adamantinomatous craniopharyngioma contains senescent cells with tumour-inducing potential

Year:

Session type: , ,

Theme:

Mario Jose Gonzalez-Meljem1,Gabriela Carreno1,John Apps1,Scott Haston1,Christina Stache1,Tomas Stanley Jacques2,5,Colin Goding3,Jesus Gil4,Cynthia Lilian Andoniadou1,Juan Pedro Martinez-Barbera1

1University College London, London, UK,2University of Oxford, Oxford, UK,3Imperial College London, London, UK,4King’s College London, London, UK,5Great Ormond Street Hospital, London, UK


The Salt Inducible Kinase 2 (SIK2) links lipid metabolism to survival of ovarian cancer metastasis

Year:

Session type: ,

Theme:

Fabrizio Miranda1,2,Shujuan Liu1,2,Sandra Herrero-Gonzalez1,2,David Mannion1,2,Stefan Knapp3,Ahmed Ahmed1,2

1Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK,22Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Women’s Centre, John Radcliffe Hospital, Oxford, UK,33Nuffield Department of Clinical Medicine, SGC, Old Road Campus Research Building, Oxford, UK


Multiregion copy number analysis reveals Wilms’ tumour genetic heterogeneity

Year:

Session type: , ,

Theme:

George Cresswell1,Borbala Mifsud1,John Apps2,3,Richard Williams2,3,Oystein Olsen3,Kathy Pritchard-Jones2,3,William Mifsud2,3,Nicholas M. Luscombe1

1The Francis Crick Institute, London, UK,2UCL Institute of Child Health, London, UK,3Great Ormond Street Hospital, London, UK